National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Fedratinib (Inrebic®). HTA ID: 21069

Fedratinib (Inrebic®) is indicated for the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis who are JAK inhibitor–naive or have been treated with ruxolitinib.

 

NCPE Assessment Process Complete
Rapid review commissioned 20/12/2021
Rapid review completed 20/01/2022
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that fedratinib not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.